🇺🇸 FDA
Patent

US 11939361

Compositions of peptide inhibitors of Interleukin-23 receptor

granted A61KA61K38/00A61K38/10

Quick answer

US patent 11939361 (Compositions of peptide inhibitors of Interleukin-23 receptor) held by Protagonist Therapeutics, Inc. expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Protagonist Therapeutics, Inc.
Grant date
Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K38/00, A61K38/10, A61K47/26, A61K47/38